Physician profile
Darrell D Wadas
NPI 1871565739
$10,339.77
in general payments reported to CMS, 2019-2025
38 companies · $24.62 in 2025
The $24.62 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,310 · 2020: $1,534 · 2021: $1,932 · 2022: $2,158 · 2023: $2,347 · 2024: $34.24 · 2025: $24.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,026.25 | 2019-2023 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,755.38 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $765.06 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $745.64 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $536.17 | 2019-2023 | |
| Pfizer INC. | $343.62 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $335.53 | 2022-2023 | Zeposia |
| Celgene Corporation | $309.61 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $303.45 | 2020-2023 | |
| Redhill Biopharma INC. | $253.01 | 2020-2022 | |
| Qol Medical, LLC | $250.88 | 2019-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $228.65 | 2020-2023 | Rebyota |
| Ardelyx, INC. | $195.12 | 2022-2023 | Ibsrela |
| Allergan, INC. | $171.37 | 2019-2020 | |
| Genzyme Corporation | $166.68 | 2022-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $138.87 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $106.11 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $100.95 | 2020-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $69.71 | 2022-2023 | Dupixent |
| Daiichi Sankyo INC. | $60.73 | 2019-2021 | |
| Braintree Laboratories, INC. | $57.51 | 2022-2023 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $55.50 | 2021-2022 | |
| Shire North American Group INC | $39.24 | 2019 | |
| Boston Scientific Corporation | $37.03 | 2019 | |
| Ucb, INC. | $32.07 | 2019 | |
| Intra-Sana Laboratories | $31.63 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Alfasigma USA, INC. | $29.82 | 2020-2021 | |
| Mylan Institutional INC. | $25.62 | 2023 | Hulio |
| Abbott Laboratories | $24.62 | 2025 | Aveir |
| Lucid Diagnostics INC. | $24.11 | 2023 | |
| Fresenius Kabi USA, LLC | $23.29 | 2023 | |
| Olympus America INC. | $20.54 | 2024 | Hanarostent Esophagus Tts(Ccc) |
| Organon LLC | $19.58 | 2023 | Hadlima |
| Evoke Pharma, INC. | $16.78 | 2020 | |
| Axonics, INC. | $15.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.20 | 2019 | |
| Echosens North America, INC. | $8.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Wadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.